Overview
Gene therapy for Hemophilia B represents one of the most transformative advances in modern hematology. Instead of repeated lifelong factor IX infusions, gene therapy aims to deliver a functional copy of the F9 gene into liver cells, enabling the body to produce its own clotting factor.
In China, rapid progress in AAV-based gene therapy platforms and clinical research infrastructure has made it increasingly possible for international patients to access advanced investigational or early-approved gene therapy programs under expert supervision.
This treatment package is designed for eligible moderate-to-severe Hemophilia B patients seeking long-term bleeding control and reduced dependence on factor replacement therapy.
What is Gene Therapy for Hemophilia B?
Gene therapy for Hemophilia B uses an adeno-associated virus (AAV) vector to deliver a correct version of the Factor IX (F9) gene into liver cells.
Once delivered:
- The liver begins producing functional Factor IX protein
- Blood clotting ability improves significantly
- Bleeding episodes are reduced or eliminated in many patients
- Routine factor IX injections may no longer be required
This is a one-time or single-infusion strategy with long-lasting effects in suitable patients.
Treatment Highlights
- One-time intravenous gene infusion (AAV-based therapy)
- Designed to restore endogenous Factor IX production
- Potential long-term reduction or elimination of bleeding episodes
- Reduced or no need for regular Factor IX replacement therapy
- Hospital-based monitoring and liver function tracking required
Who May Benefit?
This treatment may be suitable for:
- Adults with severe or moderately severe Hemophilia B
- Patients with frequent bleeding episodes
- Individuals dependent on regular Factor IX infusions
- Patients without neutralizing antibodies to AAV vectors (screening required)
Not all patients are eligible—comprehensive pre-treatment evaluation is required.
Pre-Treatment Evaluation in China
Before therapy, patients typically undergo:
- Factor IX activity level testing
- AAV antibody screening
- Liver function assessment (ALT, AST, bilirubin)
- Hepatitis B/C and infectious disease screening
- Genetic confirmation of F9 mutation
- Imaging and baseline bleeding assessment
Treatment Process in China
- Medical Consultation & Eligibility Screening
- Review of medical history and prior bleeding patterns
- Pre-Infusion Workup (7–10 days)
- Laboratory testing and immune screening
- Gene Therapy Infusion
- Single IV infusion of AAV-F9 vector under hospital supervision
- Post-Treatment Monitoring (2–4 weeks in China)
- Liver enzyme monitoring
- Factor IX expression tracking
- Safety and immune response evaluation
- Long-Term Follow-Up
- Regular check-ups for 12–24 months
Expected Outcomes
Clinical studies of modern AAV-FIX therapies have shown:
- Significant reduction in annual bleeding rates
- Sustained Factor IX expression in many patients
- Reduced or eliminated need for prophylactic injections
- Improved quality of life and mobility
Individual results may vary depending on immune response and baseline condition.
Why China for Gene Therapy?
- Rapidly expanding gene therapy clinical ecosystem
- Access to innovative AAV-based research programs
- Multidisciplinary hematology centers
- Lower overall treatment costs compared to Western countries
- Integrated medical travel support (visa, accommodation, translation, care coordination)
Package Includes
- Specialist hematology consultation
- Genetic and eligibility screening
- Hospital admission coordination
- Gene therapy infusion procedure
- Inpatient monitoring and nursing care
- Liver and safety monitoring
- Medical interpreter services
- Treatment coordination and follow-up plan
